{"id":17424,"date":"2024-12-10T16:55:04","date_gmt":"2024-12-10T08:55:04","guid":{"rendered":"https:\/\/flcube.com\/?p=17424"},"modified":"2024-12-10T16:55:06","modified_gmt":"2024-12-10T08:55:06","slug":"eli-lillys-jaypirca-demonstrates-superiority-in-bruin-cll-321-study-for-cll-sll-treatment","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=17424","title":{"rendered":"Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment"},"content":{"rendered":"\n

US pharmaceutical major Eli Lilly and Company (NYSE: LLY<\/a>) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton’s tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.<\/p>\n\n\n\n

BRUIN CLL-321 Study Design and Primary Endpoint<\/strong>
The BRUIN CLL-321 study is designed to assess the efficacy of pirtobrutinib in adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL\/SLL) who have previously been treated with a covalent BTK inhibitor. The study has already met its primary endpoint of progression-free survival (PFS) at the preliminary analysis, with pirtobrutinib showing superiority over the investigator’s choice of idelalisib plus rituximab (IdelaR) or bendamustine plus rituximab (BR).<\/p>\n\n\n\n

Consistent Improvement in Progression-Free Survival<\/strong>
The final prespecified analysis results revealed at ASH 2024 demonstrated consistent improvement in PFS for patients treated with pirtobrutinib. The treatment reduced the risk of relapse, disease progression, or death by 46% compared to IdelaR or BR, highlighting the potential of pirtobrutinib as a more effective therapy for patients with CLL\/SLL who have previously received a covalent BTK inhibitor.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the…<\/p>\n","protected":false},"author":1,"featured_media":17426,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,199,911],"class_list":["post-17424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-eli-lilly","tag-nyse-lly"],"yoast_head":"\nEli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=17424\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment\" \/>\n<meta property=\"og:description\" content=\"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=17424\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-12-10T08:55:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-10T08:55:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1055.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"672\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\\\/SLL Treatment\",\"datePublished\":\"2024-12-10T08:55:04+00:00\",\"dateModified\":\"2024-12-10T08:55:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424\"},\"wordCount\":203,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1055.png\",\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"Eli Lilly\",\"NYSE: LLY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17424#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=17424\",\"name\":\"Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\\\/SLL Treatment - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1055.png\",\"datePublished\":\"2024-12-10T08:55:04+00:00\",\"dateModified\":\"2024-12-10T08:55:06+00:00\",\"description\":\"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=17424\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1055.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/12\\\/1055.png\",\"width\":1080,\"height\":672,\"caption\":\"Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\\\/SLL Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=17424#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\\\/SLL Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment - Insight, China's Pharmaceutical Industry","description":"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=17424","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment","og_description":"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.","og_url":"https:\/\/flcube.com\/?p=17424","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-12-10T08:55:04+00:00","article_modified_time":"2024-12-10T08:55:06+00:00","og_image":[{"width":1080,"height":672,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1055.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=17424#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=17424"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment","datePublished":"2024-12-10T08:55:04+00:00","dateModified":"2024-12-10T08:55:06+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=17424"},"wordCount":203,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=17424#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1055.png","keywords":["Academic conference","Clinical trial results","Eli Lilly","NYSE: LLY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=17424#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=17424","url":"https:\/\/flcube.com\/?p=17424","name":"Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=17424#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=17424#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1055.png","datePublished":"2024-12-10T08:55:04+00:00","dateModified":"2024-12-10T08:55:06+00:00","description":"US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the Phase III BRUIN CLL-321 study for its Jaypirca (pirtobrutinib), an oral, non-covalent Bruton's tyrosine kinase (BTK) inhibitor, at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=17424#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=17424"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=17424#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1055.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1055.png","width":1080,"height":672,"caption":"Eli Lilly's Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=17424#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL\/SLL Treatment"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/12\/1055.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=17424"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17424\/revisions"}],"predecessor-version":[{"id":17427,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/17424\/revisions\/17427"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/17426"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=17424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=17424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=17424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}